Eric Halioua

Company: PDC*line Pharma

Job title: President & Chief Executive Officer

Seminars:

New Class of Antigen-Specific Cancer Active Immunotherapies based on an Off-the-Shelf Antigen Presenting Cell line (PDC*line) 1:30 pm

PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors Applying the technology for any cancerRead more

day: Day Two